$36.97▴ 0.16%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
Value-trap risk
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Harrow, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
- What Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target?